Stephens & Co. keeps Guardant Health at "overweight" with $210 price target
Stephens & Co. kept its rating on Guardant Health at "overweight" and its price target at $210, according to TradingView. That target implies 44.2% upside from the November 19 close of $145.59. The three most recent analyst notes on the company over the past 30 days set price targets between $190 and $210.
In 25 seconds
- Stephens & Co. reiterates an "overweight" rating on Guardant Health.
- The price target remains at $210 per share.
- The target implies 44.2% upside from the November 19 close of $145.59.
IASummary generated by artificial intelligence from a story by TradingView. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.